Modern anti-doping laboratories continuously adapt to new pharmacological threats. Consequently, redalsomatropin alfa drug testing has become a priority for regulatory bodies. Redalsomatropin alfa, also known as JR-142, is a recombinant fusion protein. It consists of a 22-kDa human growth hormone (hGH) and human serum albumin (HSA). This design significantly extends its half-life in the body. The drug currently undergoes Phase III clinical development for treating growth hormone deficiency. Its potential misuse in sports stems from the anabolic and lipolytic effects of growth hormone analogues.

Challenges in Immunoassay Detection

Standard immunoassays often struggle to identify long-acting growth hormones (LAGHs). Specifically, researchers evaluated Kit 1 and Kit 2 of the routine rhGH assays used in laboratories. They found that only Kit 2 could recognize the fusion protein. However, the cross-reactivity was significantly lower than that of native hGH. This limitation suggests that athletes using the drug might escape detection if laboratories rely solely on immunoassays. Therefore, developing a more robust detection strategy is vital for maintaining sports integrity.

Improving Redalsomatropin Alfa Drug Testing Through LC-HRMS/MS

To address these gaps, scientists developed a qualitative initial testing procedure (ITP). They combined affinity purification with Liquid Chromatography-High Resolution Tandem Mass Spectrometry (LC-HRMS/MS). The process uses magnetic beads conjugated with GHR-Fc for sample extraction. Following extraction, researchers perform tryptic digestion to identify specific protein markers unique to the fusion protein. This method proves highly sensitive and specific. Method validation demonstrated that it detects the drug at concentrations as low as 50 ng/mL.

Future Implications for Sports Medicine

This advancement offers more than just specific detection of JR-142. The LC-HRMS/MS assay can expand to test multiple LAGHs simultaneously. This scalability enhances the efficiency of anti-doping laboratories worldwide. Furthermore, it creates a significant deterrent against the misuse of synthetic hormones in competitive sports. Clinicians in sports medicine must stay informed about these evolving detection capabilities to ensure compliance and athlete health.

Frequently Asked Questions

What is redalsomatropin alfa?

It is a long-acting growth hormone analogue currently in clinical trials. It fuses human growth hormone with human serum albumin to increase its half-life, allowing for less frequent dosing.

Why is redalsomatropin alfa drug testing difficult with standard kits?

The attachment of albumin to the hGH molecule interferes with antibody binding in standard immunoassays. This interference results in significantly reduced cross-reactivity and potential false-negative results.

How does LC-HRMS/MS improve detection?

LC-HRMS/MS identifies the unique peptide sequences of the drug after affinity purification. This method provides high sensitivity and specificity, allowing detection even at low concentrations in biological samples.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional endorsement of specific testing protocols. Refer to the latest local and national guidelines for clinical practice.

References

Walpurgis K et al. Detection of the GH Analogue Redalsomatropin Alfa in Sports Drug Testing: Immunological Approaches and LC-HRMS/MS. Drug Test Anal. 2026 Apr 21. doi: 10.1002/dta.70075. PMID: 42014927.

World Anti-Doping Agency. The 2024 Prohibited List International Standard. WADA-AMA.org. Published January 1, 2024.

JCR Pharmaceuticals. JCR Pharmaceuticals Initiates Phase III Trial of JR-142 in Japan. News Release. December 2024.